Copyright © 2011-2015 Ascletis Inc. All rights reserved.

News & Events

Investor Center

Careers

Pipeline

Partnership

About  Us

About Us

Research & Development

Research & Development Pipeline Partership Investor Center News & Events Careers
Home

中文

Contact
Contact    Home    Home-Ch 浙ICP备11050387号

ASCLETIS INNOVATION

歌礼创新
Press Releases
More Ascletis News
News & Events

Aug 31, 2015   Ascletis Initiates Phase II Clinical Trial of Its Interferon-Free HCV Combination Regimen in Taiwan  >>

20150831IFN-free.pdf

Sep 02, 2015   Ascletis Secures US$ 35 Million Financing  >>

20150902Financing.pdf

Oct 19, 2015   Dr. Jinzi Wu was Invited to Spoke at the Gates Foundation 11 th Annual Grand Challenges Conference  >>

20151019GrandChallenge.pdf

Dec 02, 2015 Hangzhou and Shaoxing, China – Goldman Sachs Invested US$20 Million in Ascletis   >>

20151202GS.pdf

Dec 03, 2015   Deputy Governor, Mrs. Liming Liang, meets with Dr. Wu and top executives from Goldman Sachs  >>

20151203DeputyGovernorCh.pdf
CCTV Report on HCV
Partnership
APASL Panel Review
Partership APASL2015Prof.Wei.pdf

Status and Treatment Trends of HCV

HCV IN CHINA

HCV

Danoprevir

HIV in China
BioDiscover Interview
Think Outside the Box

公司声明




2015年6月9日/近日,一篇名为 《特大号外:美国公司宣布人类 已经攻克癌症》(以下简称《特 大号外》)的文章在国内各大网 站、论坛、微博及微信朋友圈等 渠道广为传播,引起公众的关注 和热议。作为文中提及的美国阿 尔尼拉姆(Alnylam)公司在国 内的战略合作企业,歌礼生物科 技(杭州)有限公司(以下简称 “歌礼公司”)接到很多患者、 医生和社会公众的咨询电话。鉴 于此,歌礼公司特发此声明以正 视听。                          

                       声明详情 >>

CompanyStatement1.pdf

Ascletis is a specialty therapeutics company dedicated to discovering

and developing important new treatments for cancer and infectious diseases.